secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001437749-26-009611
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals stockholders approve increased evergreen share reserve cap at annual meeting
--------------------------------------------------------------------------------

- Stockholder approved Amendment No. 1 to 2021 Omnibus Incentive Plan, effective March 23, 2026.
- New annual share increase is lesser of 3,187,234 shares, 5% of outstanding, or Board-determined amount.
- Class I directors Chaim Hurvitz and Michael Taylor re-elected with 9.86M and 9.89M For votes.
- Appointment of Weinberg & Company as auditor ratified with 17.35M For (98.5% of votes cast).
- Non-binding advisory vote on named executive officer compensation passed with 9.97M For.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926009611/0001437749-26-009611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926009611/nrxp20260324_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-009611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer